Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer DOI Creative Commons

Emily Wolf,

Guilherme Sacchi de Camargo Correia,

Shenduo Li

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(2), P. 128 - 128

Published: Jan. 27, 2025

Lung cancer remains the leading cause of cancer-related mortality worldwide. Non-small-cell lung (NSCLC) is most common type cancer, with nearly half all patients diagnosed at an advanced stage. Immune checkpoint inhibitors (ICIs) harness host immune system to combat malignant cells. ICIs, which target programmed death-ligand 1 (PD-L1), cell death (PD-1), and cytotoxic T-cell lymphocyte-4 (CTLA-4), have transformed treatment landscape for NSCLC. While a subset experiences long-term durable response, will develop disease progression. New drugs targeting novel pathways are being tested in clinical trials improve efficacy immunotherapy overcome resistance patterns. This review aims summarize currently available ICIs NSCLC describe emerging immunotherapies recently published data from phase I/II trials.

Language: Английский

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends DOI Creative Commons
Qian Sun, Zhenya Hong, Cong Zhang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Aug. 28, 2023

Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-L1, novel LAG-3 drugs have also been approved clinical application. With the widespread use of drug, we must deeply analyze dilemma agents seek a breakthrough treatment prospect. Over past decades, these demonstrated dramatic efficacy, especially patients with melanoma non-small cell lung cancer (NSCLC). Nonetheless, field broad concept solid tumours, non-specific indications, inseparable immune response side effects, unconfirmed progressive disease, complex regulatory networks resistance are four barriers that limit its Fortunately, successful trials ICB combination therapies, advent era oncolytic virus gene editing, technical mRNA vaccines nano-delivery systems made remarkable breakthroughs currently. In this review, enumerate mechanisms each checkpoint targets, associations between tumour mutation burden, key or signalling pathways, specific evidence efficacy classical targets new among different types put forward dialectical thoughts on drug safety. Finally, discuss importance accurate triage based recent advances predictive biomarkers diagnostic testing techniques.

Language: Английский

Citations

250
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment DOI Open Access
Antonio Passaro, Maise Al Bakir, Emily G. Hamilton

et al.

Cell, Journal Year: 2024, Volume and Issue: 187(7), P. 1617 - 1635

Published: March 1, 2024

Language: Английский

Citations

150
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study DOI Creative Commons
C. Jillian Tsai, T. Jonathan Yang, Narek Shaverdian

et al.

The Lancet, Journal Year: 2023, Volume and Issue: 403(10422), P. 171 - 182

Published: Dec. 15, 2023

Language: Английский

Citations

125
Emerging evidence and treatment paradigm of non-small cell lung cancer DOI Creative Commons
Si‐Yang Maggie Liu,

Mei-Mei Zheng,

Yi Pan

et al.

Journal of Hematology & Oncology, Journal Year: 2023, Volume and Issue: 16(1)

Published: April 17, 2023

Abstract Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width depth of clinical trials have also dramatically improved an unprecedented speed. personalized treatment paradigm evolved every year. In this review, we summarize the promising agents that shifted for NSCLC patients across all stages, including targeted immunotherapy using checkpoint inhibitors. Based recent evidence, propose algorithms several unsolved issues, which are being explored ongoing trials. results these likely to impact future practice.

Language: Английский

Citations

59
Non-small-cell lung cancer DOI
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn

et al.

Nature Reviews Disease Primers, Journal Year: 2024, Volume and Issue: 10(1)

Published: Sept. 26, 2024

Language: Английский

Citations

53
New promises and challenges in the treatment of advanced non-small-cell lung cancer DOI

May-Lucie Meyer,

Bailey G Fitzgerald,

Luís Paz-Ares

et al.

The Lancet, Journal Year: 2024, Volume and Issue: 404(10454), P. 803 - 822

Published: Aug. 1, 2024

Language: Английский

Citations

51
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer DOI Creative Commons

Weishi Cheng,

Kai Kang, Ailin Zhao

et al.

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: July 27, 2024

Abstract Cancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cancer. Programmed death receptor-1/programmed receptor ligand-1 (PD-1/PD-L1) cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) are some of most common promising targets in ICIs. Compared to ICI monotherapy, which occasionally demonstrates resistance limited efficacy, dual blockade immunotherapy targeting PD-1/PD-L1 CTLA-4 operates at different stages activation with synergistically enhancing responses against cells. This emerging therapy heralds a new direction immunotherapy, which, however, may increase risk drug-related adverse reactions while improving efficacy. Previous clinical trials explored combination strategy anti-PD-1/PD-L1 anti-CTLA-4 agents cancer, yet its efficacy remains be unclear inevitable incidence immune-related events. The recent advent bispecific antibodies has made this sort more feasible, aiming alleviate toxicity without compromising Thus, review highlights role treating further elucidates pre-clinical mechanisms current advancements trials. Besides, we also provide novel insights into potential combinations therapies other strategies optimize future mode

Language: Английский

Citations

31
Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer DOI Creative Commons
Yue Zeng, Chunhong Hu, Yizheng Li

et al.

Nature Medicine, Journal Year: 2024, Volume and Issue: 30(6), P. 1680 - 1688

Published: May 13, 2024

Abstract Emotional distress (ED), commonly characterized by symptoms of depression and/or anxiety, is prevalent in patients with cancer. Preclinical studies suggest that ED can impair antitumor immune responses, but few clinical have explored its relationship response to checkpoint inhibitors (ICIs). Here we report results from cohort 1 the prospective observational STRESS-LUNG study, which investigated association between and efficacy first-line treatment ICIs advanced non-small-cell lung was assessed Patient Health Questionnaire-9 Generalized Anxiety Disorder 7-item scale. The study included 227 111 (48.9%) exhibiting who presented (Patient score ≥5) anxiety (Generalized at baseline. On primary endpoint analysis, baseline exhibited a significantly shorter median progression-free survival compared those without (7.9 months versus 15.5 months, hazard ratio 1.73, 95% confidence interval 1.23 2.43, P = 0.002). secondary associated lower objective rate (46.8% 62.1%, odds 0.54, 0.022), reduced 2-year overall 46.5% 64.9% (hazard for death 1.82, 1.12 2.97, 0.016) detriments quality life. exploratory analysis indicated group showed elevated blood cortisol levels, adverse outcomes. This suggests there an worse outcomes cancer treated ICIs, highlighting potential significance addressing management. ClinicalTrials.gov registration: NCT05477979 .

Language: Английский

Citations

27
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges DOI Creative Commons

Yuchu Xiang,

Xudong Liu, Yifan Wang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: April 9, 2024

Resistance to targeted therapy and immunotherapy in non-small cell lung cancer (NSCLC) is a significant challenge the treatment of this disease. The mechanisms resistance are multifactorial include molecular target alterations activation alternative pathways, tumor heterogeneity microenvironment change, immune evasion, immunosuppression. Promising strategies for overcoming development combination therapies, understanding better use novel drug targets, identification biomarkers, modulation so on. Ongoing research into new therapeutic approaches hold great promise improving outcomes patients with NSCLC. Here, we summarize diverse driving NSCLC latest potential promising overcome help who suffer from

Language: Английский

Citations

26
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back DOI Creative Commons
Annapaola Mariniello, Maxime Borgeaud, Marc Weiner

et al.

BioDrugs, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 15, 2025

Immunotherapy with checkpoint inhibitors has become the cornerstone of systemic treatment for non-oncogene addicted non-small-cell lung cancer. Despite its pivotal role, a significant proportion patients—approximately 70–85%—either exhibit primary resistance to PD-1 blockade or develop acquired following an initial benefit, even in combination chemotherapy and/or anti-CTLA-4 agents. The phenomenon and immunotherapy represents critical clinical challenge, largely based on our incomplete understanding mechanisms action immunotherapy, resulting lack accurate predictive biomarkers. Here, we review definitions explore proposed resistance, including those related tumor microenvironment, factors, intrinsic characteristics. We also discuss translational data adaptive changes within cells immune infiltrate exposure inhibitors. Lastly, offer comprehensive overview current emerging therapeutic strategies designed prevent counteract resistance.

Language: Английский

Citations

2